The tool foramen" for the prevention and treatment of endometritis in cows

 

(57) Abstract:

Usage: in veterinary gynecology. The invention consists in that it contains as active substances, furacilin of 7.0 to 8.0 wt.% and karbaholina 0,025-0,033 wt.%, and in the foaming base included: sodium bicarbonate 18,0-22,0 wt.%, boric acid 22,0-27,0 wt.%, citric acid is 4.0 to 6.0 wt.%, starch 8.0 to 12.0 wt.%, calcium stearate of 0.45-0.56 wt. % polyethylene glycol-115 of 8.5-11.5 wt.%, sodium dodecyl sulphate 0,28-of 1.05 wt.% and glucose - rest. The invention solves the problem of improving the content, fast growing concentration and uniform distribution of active substances by increasing the volume of the foam. In addition, when carrying out the invention is enhanced anti-inflammatory and antibacterial effects, increases tone and increases the contraction of the uterus muscles. 3 table.

The invention relates to the field of veterinary medicine, in particular veterinary gynecology, and can be used for the prevention and treatment of postpartum endometritis.

The closest tool adopted for the prototype is PMS (foaming uterine candles) [1]. The preparation contains as active substances desimal, calcium stearate and emulsifier.

The disadvantages of the drug is weak solubility and low levels of furazolidone and delimiting comprising activetestsuite substances, and the Foundation does not provide a sufficient volume of foam.

The invention solves the problem of improving the content, fast growing concentration and uniform distribution of active substances in the product by increasing the volume of the foam.

In addition, when carrying out the invention is enhanced anti-inflammatory and antibacterial effects, increase the tone and contractility of the muscles of the uterus.

The invention consists in that the means for prevention and treatment of endometritis in cows, including activetestsuite substance - furan drug, a drug that enhances contractility of the uterus, and foaming basis differs according to the invention by the fact that it introduced as activitiesthese substances furacilin and foaming base contains boric acid, glucose, polyethylene glycol-115, sodium dodecyl sulphate and components respectively represented as follows (wt.%):

Furacilin - 7,0 - 8,0

K0 - 6,0

Starch - 8,0 - 12,0

The glycol-115 - 8,5 - 11,5

Sodium dodecyl sulphate - from 0.88 to 1.05

Calcium stearate - 0,45 - 0,56

Glucose - Rest

Get the claimed composition as follows. Give and contribute in an electric mill the following ingredients: furacilin, karbaholina, starch, glucose, polyethylene glycol-115, sodium dodecyl sulphate and calcium stearate. Within one minute in the mill grind them and mix until smooth. Weigh and add to the resulting mass of boric, citric acid, sodium bicarbonate and produce mechanical mixing (see tab. 1 in the end of the description).

Then the resulting mass is transferred into the hopper of the press, where it is automatically measured 10.0 weight and pressure of 25 psi for 1-2 seconds to get suppositories cylindrical shape with a pointed end (length 8.5 cm, diameter 13 mm). Suppositories gray-yellow color, have high storage stability and can be manufactured in the factory as a finished dosage form.

Ready suppositories placed in a plastic bag of 10 pieces, provided with a label and hermetically closed.

The drug is administered intrauterine dose of 1 suppository to Prometric.

Tests of funds on animals carried out in comparison with known drug PMS (PL. 2 and 3 at the end of the description).

The results showed that the use of "Foramena" after surgical separation of placenta with the purpose of prevention of endometritis compared with PMS allows you to increase the average prophylactic efficacy 26.2%, reduce the service period is 63 days, to reduce the index of fertilization 1.33, to increase stability from 1st insemination 13.9%.

In the treatment of postpartum catarrhal-purulent endometritis in cows offered the drug in comparison with the known average decreases by one injection of the drug, duration of treatment is shortened by one day, the clinical recovery occurs earlier in 4.8 days, the service period is reduced by 20.6 per day, decreases the index of fertilization 0.40 and 8.9% increases the number of pregnant animals from 1st insemination.

The advantage Foramena" compared with PMS is to increase therapeutic and prophylactic efficacy by increasing the volume of foam that promotes rapid in increasing concentration and uniform distribution of active substances in the uterine cavity, and Teste taken and allows you to reap the economic benefits by reducing the cost of treatment.

The source of information

1. Interim guidance on the application of foaming uterine candles (PMS) in veterinary practice (during 1984 - 1985), approved the BS of the Ministry of agriculture of the USSR 6.03.84,, 115-6A.

The remedy for the prevention and treatment of endometritis in cows, including activetestsuite substance karbaholin and foaming base containing sodium bicarbonate, citric acid, starch and calcium stearate, wherein as activitiesthese substance further comprises furacilin and foaming base further comprises boric acid, glucose, polyethylene glycol-115 and sodium dodecyl sulphate in the following ratio, wt.%:

Furacilin - 7,0 - 8,0

Karbaholin - 0,025 - 0,033

Sodium bicarbonate - 18,0 - 22,0

Boric acid - 22,0 - 27,0

Citric acid - 4,0 - 6,0

Starch - 8,0 - 12,0

The glycol-115 - 8,5 - 11,5

Sodium dodecyl sulphate - from 0.88 to 1.05

Calcium stearate - 0,45 - 0,56

Glucose - Rest

 

Same patents:

The invention relates to a crystalline form of 7-[2-(2-amino - 1,3-thiazol-4-yl)-2-methoxyimino)acetamido] -3-[(FSD-2-ylcarbonyl) thiomethyl]-3-cefem-4-carboxylic acid (also known as 7-[2-(2-amino-4-thiazolyl)-2-methoxyimino)acetamido] -3-[2 - (uranilkarbonatov)-8-oxo-5-thia-1-azabicyclo[4,2,0] Oct-2-ene-1-carboxylic acid), also known as ceftiofur, formula 1 circuits in the formula next

The invention relates to pharmacology, and relates to new 5-thia-1,4-diazabicyclo[4.2.0]octane-3,8-dioxo-derivatives of the General formula 1

< / BR>
where R1represents hydrogen, halogen; R2represents hydrogen, halogen, amino, РhСН2СОNН, РhОСН2СОNН, phthalimido, the МеNНСОС6H4SLEEP, 3-o-chlorophenyl-5-METI-isoxazolyl-4-carbylamine; R3represents hydrogen, alkyl, benzyl, heterocyclic ring, for example, isoxazol, pyrazole; n is 1 or 2

The invention relates to new derivatives of hydroxamic acids, possessing valuable pharmacological properties, in particular showing the properties of an inhibitor of collagenase, which can be used to delay the development or prevention of diseases of degeneration of the joints, such as rheumatoid arthritis or osteoarthritis, or in the treatment of invasive tumors, atherosclerosis or multiple sclerosis, as well as the way they are received, intermediate products for their production, pharmaceutical preparation and method thereof
The invention relates to medicine, namely to intensive care

The invention relates to new compounds with dual activity, namely the activity of inhibiting angiotensin converting enzyme, and the activity of inhibiting neutral endopeptidase and to methods of producing these compounds
The invention relates to medicine, namely to the chemical-pharmaceutical industry and relates to a method of obtaining a tablet form of the drug
The invention relates to medicine, gynecology

The invention relates to medicine, namely, neurology, and can be used for the treatment of Parkinson's disease and parkinsonism phenomena

The invention relates to medicine, namely to surgery
The invention relates to the field of production of drugs; specifically, it concerns a method of obtaining ethoxylated starch (oke), which finds use as a blood substitute resuscitation actions hemodynamic plasma substitute

acyl(hydr)oxosteroid with antitumor activity" target="_blank">

The invention relates to the chemistry of steroids and related specifically to 3-OR-di-(2-chloroethyl)aminecontaining 11-acyl(HYDR)oxosteroid with antitumor activity General formula (I), where R = COCH2C6H4N(CH2CH2Cl)2; R1=-OCOCH3+-CCH;-OCOC2H5+-H; R2= H, OCOH, COCH3

alkenylphenol and their pharmaceutically compatible salts" target="_blank">

The invention relates to new derivatives 3alkenylphenol General formula I

< / BR>
where one of R1and R2means-СОR4, -CN , -CH2R5, halogen, -CH = СНR6or Q and the other is hydrogen or lower alkyl, or both together represent-laktamovogo ring; R3is hydrogen, lower alkyl, arylalkyl, allyl or ottsepleny in vivo radical; R4is hydrogen, lower alkyl, lower alkoxy, benzyloxy, amino, lower alkylamino or lower alkyl-lower alkoxyamino, R5- hydroxyl group, -ОСОNНR7, -ОСОNН2or a five - or six-containing N, S and/or O heteroaromatic linked through the nitrogen atom of the ring; R6- -SP or-Cho; R7- THE PINES2CL; Q is a five - or six-containing N, S and/or O heteroaromatic ring, and n = 0, 1 or 2, and pharmaceutically compatible salts of these compounds
Up!